Substances · Cathinone derivatives
α-PHiP
- Preferred name
- α-PHiP
- IUPAC name
- 4-methyl-1-phenyl-2-pyrrolidin-1-ylpentan-1-one
- Parent CAS number (reference)
- 2181620-71-1
- Molecular formula
- C16H23NO
- Molecular weight
- 245.36 g/mol
- InChIKey
- UOZWZANRCOALQL-UHFFFAOYSA-N
- PubChem
- CID 59809191
- Source
- PubChem
- Verified synonyms & catalog abbreviations
-
alpha-PIHP alpha-PHiP alpha-Pyrrolidinoisohexaphenone αPHiP α PHiP a-PHiP aPHiP a-PiHP
Verified Neurochemical & Toxicological Intelligence
alpha-PiHP (alpha-Pyrrolidinoisohexanophenone / alpha-PHiP)
Receptor Telemetry & Mechanism of Action
Branched acyl-chain positional isomer of alpha-PHP (4-methylpentan-1-one backbone, distinct from ring-methylated MPHP) acting as a pure, catecholamine-selective monoamine transporter blocker (NDRI) without releasing activity. WHO 45th ECDD data show pronounced selectivity for DAT (IC50 = 16.5 nM, Ki = 35.7 nM — ~12-fold more potent at uptake blockade and ~16-fold higher affinity than cocaine) and NET (IC50 = 41.4 nM, Ki = 340 nM) while sparing SERT (IC50 > 10,000 nM, Ki > 7,500 nM). High DAT selectivity drives an intense dopaminergic rush and extreme repeated exposure compulsivity.
Biotransformation & Active Metabolites
Expected to follow related pyrrolidinophenone pathways (keto reduction, oxidations, and N-dealkylation); WHO 45th ECDD notes no controlled human clinical pharmacokinetic studies exist.
Temporal Pharmacokinetics
Sharp, intensely reinforcing dopaminergic stimulant producing rapid mood elevation, ego inflation, thought acceleration, and heightened libido alongside a very narrow margin before agitation and paranoia.
- Onset 30–60 minutes oral (1–2 minutes mucosal; ~1 minute vaporized)
- Peak Window 1–2 hours oral (20–45 minutes mucosal)
- Total Window 2–5 hours oral (2–4 hours mucosal; 1–3 hours vaporized)
- Residual / Half-Life 6–12 hours of residual wakefulness, vasoconstriction, and insomnia across all routes; formal human plasma half-life is unverified.
Active at 3–5 mg orally and 1–3 mg mucosal. Because its intense DAT-driven rush subsides within 2–5 hours while leaving 6–12 hours of residual cardiovascular and adrenergic stimulation, alpha-PiHP triggers relentless compulsive repeated exposure—rapidly escalating into acute paranoid psychosis, severe vasoconstriction, hyperthermia, rhabdomyolysis, and documented single-substance fatalities.
Quantitative Response Spectrum (Published Literature)
Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.
3–5 mg oral (mucosal: 1–3 mg; vaporized: 1–2 mg)
Immediate crisp alertness, subtle focus intensification, and reduced fatigue.
Slight heart-rate elevation and appetite suppression.
5–15 mg oral (mucosal: 3–10 mg; vaporized: 2–10 mg)
Clear dopaminergic mood lift, talkativeness, task fixation, and confident energy.
Moderate pulse and blood-pressure increase, dry mouth, and light sweating.
15–30 mg oral (PMC11051472 10–30 mg; mucosal: 10–25 mg; vaporized: 10–20 mg)
Powerful mood-elevating rush, ego inflation, disinhibition, rapid thought acceleration, and strong urge to redose.
Marked tachycardia, hypertension, cold extremities from vasoconstriction, jaw tension, and dry mucous membranes.
30–50 mg oral (mucosal: 25–40 mg; vaporized: 20–30 mg)
Compulsive repeated exposure fixation, hyper-vigilance, severe anxiety, logorrhoea, and emerging paranoid ideation.
Strong peripheral vasoconstriction, tremors, bruxism, dehydration, and rapid heart rate.
50+ mg oral (mucosal: 40+ mg; vaporized: 30+ mg)
Severe paranoid psychosis, hallucinations, disorientation, delirium, or sudden loss of consciousness.
Extreme tachycardia and hypertension, hyperthermia, rhabdomyolysis, respiratory alkalosis, and fatal cardiac arrest.
Interaction Matrix & Critical Contraindications
Critical Hazard — Never Combine
16.5 nM DAT and 41.4 nM NET blockade under MAO inhibition triggers rapid, fatal hypertensive crisis and cardiac arrhythmia.
Extreme additive catecholaminergic cardiotoxicity, coronary vasospasm, hyperthermia, and convulsions.
Tramadol precipitates seizures; opioids risk fatal delayed respiratory arrest once alpha-PiHP's short 2–4 hour peak drops off.
Elevated Hazard — Avoid
Stimulation masks depressant intoxication until sudden collapse; polydrug combinations feature prominently in European post-mortem alpha-PiHP cases.
Severely compounds risk of acute delusional mania, panic, and erratic behavioral emergencies.
Caution / Receptor Attenuation
Frequently triggers acute paranoia, hallucinations, and spike in heart rate.
Adds peripheral tremors, tachycardia, and vasoconstriction.
Structural Isomer & Sibling Comparison
alpha-PiHP is the branched acyl-chain isomer of alpha-PHP (both C16H23NO, 245.37 g/mol). Compared to alpha-PVP and alpha-PHP, alpha-PiHP displays higher DAT-over-NET selectivity (DAT IC50 16.5 nM vs. NET 41.4 nM) and a shorter primary plateau (2–5 h oral vs. 2–8 h for alpha-PHP), but carries equally fierce—or stronger—anecdotal repeated exposure compulsivity. It is ~10-fold more potent at DAT than NEP.
Physicochemical Stability & Storage
Physical Form: Odorless white to off-white crystalline solid, fine powder, or rock-like crystal chunks as the monohydrochloride salt (MW 281.8 g/mol). · Soluble in water and PBS (pH 7.2, ~10 mg/mL), DMSO (~5 mg/mL), DMF (~3 mg/mL), ethanol (~3 mg/mL), and methanol (~1 mg/mL).
Store tightly sealed in a cool, dry, light-resistant container.
Cross-Tolerance & Dependence Profile
Extremely high psychological addiction and binge-compulsion liability. Rapid acute tolerance within hours; cross-tolerant with alpha-PVP, alpha-PHP, MDPHP, NEP, and cocaine (halving in 3–7 days, baseline in 1–2 weeks). Multi-day binges reliably provoke stimulant psychosis.
Codes on this card
Short meanings for the abbreviations printed with this substance.
DAT
Dopamine transporter
DAT is the protein that collects dopamine back from the gap between nerve cells. A card that names DAT is quoting a laboratory result about that protein.
NET
Norepinephrine transporter
NET is the protein that collects norepinephrine, also called noradrenaline, back into the nerve cell. Cards cite it when a lab report shows activity at that transporter.
SERT
Serotonin transporter
SERT is the protein that collects serotonin back into the nerve cell. A higher number than at DAT means the serotonin transporter needed more concentration to reach the halfway point.
SNDRA / NDRI
Releaser or reuptake blocker
An SNDRA is carried in and the cell releases serotonin, norepinephrine, and dopamine. An NDRI mainly slows the vacuum at norepinephrine and dopamine. The class line says which one the papers describe.
EC₅₀ / IC₅₀
Halfway concentration
EC50 is the concentration where a lab saw half of the maximum measured effect. IC50 is the concentration where it saw half of the maximum block. Smaller means that halfway point came at a lower concentration.
ratio
Selectivity ratio
A selectivity ratio divides two halfway numbers, such as SERT EC50 by DAT EC50, to show which target the assay reached first. The direction of the division has to be stated, or the number flips.
5-HT ↑↑
Serotonergic Overload (Serotonin Toxicity)
A potentially fatal medical emergency caused by excessive synaptic serotonin (for example when mixing two serotonin releasers, MAOIs, or tramadol), marked by hyperthermia and neuromuscular rigidity.
HR / Naczynia
Vasoconstriction & Cardiovascular Load
Narrowing of peripheral blood vessels, elevated blood pressure, and rapid heart rate driven by strong noradrenergic and dopaminergic stimulation.
Chemical Architecture & Structural Profile
α-PHiP (4-methyl-1-phenyl-2-pyrrolidin-1-ylpentan-1-one) is a reference compound belonging to the Cathinone derivatives class, characterized by the molecular formula C16H23NO and a molar mass of 245.36 g/mol. The parent molecule is indexed under CAS registry number 2181620-71-1 and in the NCBI PubChem database as CID 59809191 (Standard InChIKey: UOZWZANRCOALQL-UHFFFAOYSA-N).
Citations
- PubChem — PubChem (2026-11-12)
Reference Toxicology & Safety Profile
In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), α-PHiP is indexed within the Cathinone derivatives structural group. As a substituted beta-ketone (cathinone derivative), this compound requires strict analytical verification and has documented contraindications with MAOIs, serotonergic agents, and other stimulants. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.
Citations
- PubChem — PubChem (2026-11-12)
Analytical Use & Laboratory Notice
This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.
Citations
- Riksdagen — Förordning (1999:58) om förbud mot vissa hälsofarliga varor — Sveriges riksdag (2026-11-12)